Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Keytruda is currently indicated in a variety of cancers, including classical Hodgkin lymphoma, primary mediastinal large ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... The main difference is BNT327 targets PD-L1 while ivonescimab ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

CEL-SCI Corporation today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company's approach to patient selection using low PD-L1 tumor expression in ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Keytruda blocks the interaction of this protein with another protein called programmed death ligand-1 (PD-L1). The interaction between these two proteins stops some specific actions of your immune ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

The approval is the 14 th for Keytruda, extending its use into a tenth tumour type, and consolidates its position as the top-selling PD-1/PD-L1 drug, having overtaken Opdivo in quarterly sales ...